Table 1. General characteristics of the study population (n=151).
| Variables | Total | IR | Non-IR | p-value* | |
|---|---|---|---|---|---|
| No. of patients | 151 | 61 | 90 | - | |
| Age at diagnosis (yr) | 33.0 (21–54) | 33.0 (21–44) | 33.5 (21–54) | 0.130 | |
| BMI (kg/m2) | 24.23 (17.07–37.95) | 27.41 (18.75–37.95) | 22.17 (17.07–34.93) | <0.001 | |
| HOMA-IR | 2.49 (0.44–16.50) | 4.54 (3.03–16.50) | 1.64 (0.44–2.86) | <0.001 | |
| MS | 60 (39.7) | 40 (65.6) | 20 (22.2) | <0.001 | |
| Hypertension | 9 (6.0) | 6 (9.8) | 3 (3.3) | 0.100 | |
| Diabetes mellitus | 5 (3.3) | 5 (8.2) | 0 (0.0) | 0.010 | |
| Nulliparous | 107 (70.2) | 43 (70.5) | 64 (71.1) | 1.000 | |
| Progestin therapy | 0.170 | ||||
| MA | 82 (54.3) | 29 (47.5) | 53 (58.9) | - | |
| MA+metformin | 69 (45.7) | 32 (52.5) | 37 (41.1) | - | |
Values are presented as median (range) or number (%).
BMI, body mass index; HOMA-IR, homeostasis model assessment-insulin resistance; MA, megestrol acetate; MS, metabolic syndrome; IR, insulin resistance.
*p-value: comparison between IR and non-IR group.